INSM
Insmed IncorporatedNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
46.96
P/S
57.74
EV/EBITDA
-29.98
DCF Value
$-148.01
FCF Yield
-2.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.4%
Operating Margin
-194.0%
Net Margin
-210.5%
ROE
-168.4%
ROA
-62.9%
ROIC
-64.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $263.8M | $-328.5M | $-1.54 |
| FY 2025 | $606.4M | $-1.28B | $-6.41 |
| Q3 2025 | $142.3M | $-370.0M | $-1.75 |
| Q2 2025 | $107.4M | $-321.7M | $-1.70 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.10
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.